MedPath

Drug Use-results Survey in Patients Infected With Hepatitis C Virus Genotype 1

Completed
Conditions
Chronic Hepatitis C Virus
Registration Number
NCT02629172
Lead Sponsor
AbbVie
Brief Summary

The main objective of this study is to evaluate the safety and effectiveness of paritaprevir/ritonavir/ombitasvir used for patients infected with HCV genotype 1 in daily practice in Japan.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
3043
Inclusion Criteria
  • HCV genotype 1 patients treated with paritaprevir/ritonavir/ombitasvir in daily practice
Exclusion Criteria
  • Patients who have been previously treated with paritaprevir/ritonavir/ombitasvir

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Percentage of Participants with Sustained Virologic Response (SVR12)12 weeks after the last dose of study drug

Hepatitis C virus ribonucleic acid less than the lower limit of quantification 12 weeks after the last dose of study drug.

Secondary Outcome Measures
NameTimeMethod
Percentage of Participants with Virologic Failure After TreatmentPost-treatment 24 weeks

Confirmed quantifiable hepatitis C virus ribonucleic acid (HCV RNA) at the end of 12 week treatment but subsequent viremia with HCV RNA greater than or equal to the lower limit of quantitation during follow-up period of 24 weeks after treatment.

Percentage of Participants with Sustained Virologic Response (SVR24)24 weeks after the last dose of study drug

Hepatitis C virus ribonucleic acid less than the lower limit of quantification 24 weeks after the last dose of study drug.

Percentage of Participants with Virologic Failure During TreatmentUp to Week 12

HCV RNA levels reach less than the lower limit of quantitation (LLOQ), then increase to greater than or equal to the LLOQ at any point during treatment.

Trial Locations

Locations (388)

Aichi Medical University Hosp /ID# 152220

🇯🇵

Nagakute, Aichi, Japan

Nagoya City University Hospital /ID# 153642

🇯🇵

Nagoya-shi, Aichi, Japan

Japanese Red Cross Narita Hosp /ID# 155894

🇯🇵

Narita-shi, Chiba, Japan

Kikkoman General Hospital /ID# 152139

🇯🇵

Noda, Chiba, Japan

Matsuyama Red Cross Hosp /ID# 152271

🇯🇵

Matsuyama, Ehime, Japan

NHO Kyushu Medical Center /ID# 153001

🇯🇵

Fukuoka-shi, Fukuoka, Japan

Fukuoka University Hospital /ID# 152272

🇯🇵

Fukuoka-shi, Fukuoka, Japan

Kurume University Hospital /ID# 152099

🇯🇵

Kurume-shi, Fukuoka, Japan

Gifu University Hospital /ID# 152993

🇯🇵

Gifu-shi, Gifu, Japan

Kusunoki Hospital /ID# 152072

🇯🇵

Fujioka, Gunma, Japan

Scroll for more (378 remaining)
Aichi Medical University Hosp /ID# 152220
🇯🇵Nagakute, Aichi, Japan

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.